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Background: Informed consent is regarded as a cornerstone of ethical healthcare research and is a requirement for
most clinical research studies. Guidelines suggest that prospective randomised controlled trial (RCT) participants
should understand a basic amount of key information about the RCTs they are being asked to enrol in in order to
provide valid informed consent. This information is usually provided to potential participants in a patient
information leaflet (PIL). There is evidence that some trial participants fail to understand key components of trial
processes or rationale. As such, the existing approach to information provision for potential RCT participants may
not be optimal. Decision aids have been used for a variety of treatment and screening decisions to improve
knowledge, but focus more on overall decision quality, and may be helpful to those making decisions about
participating in an RCT. We investigated the feasibility of using a tool to identify which items recommended for
good quality decision making are present in UK PILs.
Methods: PILs were sampled from UK registered Clinical Trials Unit websites across a range of clinical areas. The
evaluation tool, which is based on standards for supporting decision making, was applied to 20 PILs. Two
researchers independently rated each PIL using the tool. In addition, word count and readability were assessed.
Results: PILs scored poorly on the evaluation tool with the majority of leaflets scoring less than 50%. Specifically,
presenting probabilities, clarifying and expressing values and structured guidance in deliberation and communication
sub-sections scored consistently poorly. Tool score was associated with word count (r = 0.802, P <0.01); there was no
association between score and readability (r = −0.372, P = 0.106).
Conclusions: The tool was feasible to use to evaluate PILs for UK RCTs. PILs did not meet current standards of
information to support good quality decision making. Writers of information leaflets could use the evaluation tool as a
framework during PIL development to help ensure that items are included which promote and support more
informed decisions about trial participation. Further research is required to evaluate the inclusion of such information.
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Informed consent forms the cornerstone of ethical require-
ments in healthcare research [1,2]. In the context of health-
care research, the giving of informed consent signifies that
an individual has made an informed and voluntary decision
about their participation in a research study. Randomised
controlled trials (RCTs) usually require all participants to
sign an informed consent document indicating that they
have understood the information they have been provided
with before they commence participation in the trial [1].
To assist in making an informed decision about partici-
pation, potential trial participants in the UK are provided
with a patient information leaflet (PIL) that contains infor-
mation about the RCT. The information included in PILs
is guided by the Declaration of Helsinki, the International
Conference on Harmonisation Good Clinical Practice
(ICH GCP) and also by national guidance such as the
National Research Ethics Service (NRES) [1,3,4]. As defined
by the guidance, the PIL should include, at minimum, in-
formation about: the purpose of the trial; procedures; inter-
ventions; possible risks and benefits; sources of finance;
potential conflicts of interest; and the researcher’s affiliation
[1,3]. The guidance for informational requirements covers
predominantly fact-based information and is standardised
at a population level [1,3].
Currently the PIL and consent form are the only com-
ponents of the consent decision making process for RCTs
that are formally regulated, through specific guidance, and
reviewed by ethics committees or internal review bodies
[1]. However, as with decisions about treatment, potential
participants vary in the amount of information they desire
when faced with a decision about trial participation [5-7].
As such, within a trial context where the information mini-
mum has been pre-determined by the guidance [1,3,4],
many potential participants’ preferences for information
may be exceeded [6] and other approaches to supporting
decision making may be required. Despite this, there is evi-
dence that some trial participants, both those considering
participation and those actively enrolled in clinical trials, fail
to understand key components of the trial processes or
rationale [8-10]. This has ranged from misunderstandings
about: risks [11]; the right to withdraw [11]; confidentiality
[12]; side effects [13]; and purpose of the trial [14]. This
suggests that in the context of trial participation, existing
approaches to information provision may be sub-optimal
and some decisions may not have been based on a full
understanding or consideration of all the relevant issues.
This may be because the information is too complex or
not designed to support an informed decision but rather
to present factual information to the potential participant.
A range of studies have explored ways of improving infor-
mation, and have tended to focus on the content and
structure of the information [8]. For example: the length
of the information sheet, that is, short versus long leaflets[10,15]; simplified or enhanced versions of the same
PIL [16,17]; patient-specific information versus generic
information [18,19]; linguistic analysis of leaflets [20];
consumer involvement in development of PILs [21]; audio-
visual information [22]; computer-based information [23];
and user testing to improve content [24].
As discussed above, the literature to date has tended
to focus on the provision of information, to improve
understanding about trial processes, with the aim of
making the consent process more ‘informed’. How-
ever, informed decision making in the context of trial
participation is a complex process and requires more
than just greater understanding or comprehension of
certain fact-based information. For example, key con-
siderations which are regarded by established theories
of decision making as being important for making
‘good’ decisions (for example considering the alternatives
(for example standard care and what that is), making
trade-offs and evaluating potential outcomes of the de-
cision [25]) might not be presented or discussed at all
during the informed consent discussion or explicit in
the PIL. These omissions may stem from the conven-
tional conceptualisation of trial participation as an act
of ‘informed consent’. This conceptualisation likely re-
lates to the ethical and regulatory requirements, rather
than viewing deliberations and decisions about partici-
pation as broader and more complex [26].
Decision aids have been developed for a variety of treat-
ment and screening decisions as a means of improving
‘informed decisions’ in particular contexts and across the
decision making process [25]. These decision aids provide
information about: the available options and any associ-
ated outcomes; personalise information by including exer-
cises to help patients think about what matters most to
them; and provide ways of communicating this with the
healthcare professional to reach a decision [25]. There is
substantial evidence to suggest that decision aids can
positively influence outcomes, such as: improving know-
ledge, especially when there is clinical equipoise; providing
accurate perceptions of outcome probabilities; and align
preferred outcomes with the choice made [25].
As discussed previously, the traditional conceptualisation
of informed consent in RCTs is as a behaviour relating to
understanding rather than promoting informed decisions.
This may have led to the information contained within PILs
being focussed on fact-based trial information rather than,
for example, what trial participation might mean for that
individual. Yet, these personal considerations do play a sig-
nificant role for people when deciding whether or not to
participate in a trial [27] and this is often the type of infor-
mation contained within treatment decision aids. As such,
it is perhaps timely to re-think the way in which decisions
about trial participation and discussions about informed
consent are supported.
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aids for use in the informed consent process for RCTs
have shown promise in that they appear to improve as-
pects of the decision making process [28-32]. Decision
aids to support decisions about trial participation have
been shown to be acceptable and valued by potential
participants [28,29]. In these studies, the decision aid
was a substitute for the existing PIL and contained all
of the required information expected to be in a PIL in
addition to those expected to be in a decision aid. Specific-
ally, decision aids in this context have been shown to im-
prove understanding about the trial and its associated
interventions [28,29], produce low levels of decision conflict
[29] and not raise anxiety [28,29]. However, these studies
had small sample sizes and were set within a hypothetical
trial context. As such, the need for further research has
been noted [28-32]. A recent study examined the extent to
which existing informed consent documents conform to
standards for encouraging good quality decision making as
laid out by International Patient Decision Aid Standards
(IPDAS) [33,34]. The evaluation tool used in the study by
Brehaut and colleagues contained two sections: a series of
items derived from the IPDAS and a set of items derived
from published guidance on informed consent [34]. Only
the first section of the tool, including items developed from
the IPDAS, was used and the majority of the included PILs
were developed in the US with approximately half being for
cancer trials [34]. Guidance for US PILs differs from that
for UK PILs with regard to whether specific information is
presented in either the information sheet or consent
form, with UK consent forms being a one-page document,
whereas US consent forms are longer and contain much of
the information contained within the UK PIL. Moreover,
the study by Brehaut and colleagues did not assess word
count or readability, both of which can contribute to under-
standing of information and length of document.
Previous research has suggested that decision aids for
trial participation have the potential to promote good
quality decision making [28,29] and specific components
of decision aids that have been applied in RCTs have
also offered promise [30,35]. Therefore, this study aimed
to assess the feasibility of assessing the extent to which
items considered important in decision aids are present
in existing UK PILs. We used the complete evaluation tool
(developed by Brehaut et al. [34]), alongside word count
and readability ‘calculators’, to evaluate PILs across a range
of clinical conditions in a UK context.
Methods
Sample of patient information leaflets
We screened the websites of 48 UK Clinical Research
Collaborations registered (full or provisional) Clinical Trial
Units (CTUs) for publicly available PILs from recently
completed or on-going RCTs. Eighteen CTUs providedcopies of such PILs on their websites. The CTU based in
the Institute of the lead researcher (KG) also provided PILs
for the study. The total population of publicly available
CTU PILs was 60. The following inclusion criteria were
applied to the population of 60 PILs: PILs for a RCT that
was on-going or completed after 2001 (to coincide with the
introduction of the European Clinical Trials Directive
2001/20/EC [36]); PILs designed for a primary RCT, that is,
not a follow-on study; and PILs designed for competent
adults making a decision about their own participation, not
proxy decision makers. PILs that were designed for cluster
RCTs, emergency research with retrospective consent and
RCTs recruiting children or healthy volunteers were ex-
cluded from the study. Subsequently, PILs were sampled
purposively, from the identified population of 60, to allow
for variation in intervention and CTU. Four main interven-
tion groups were identified: drug; surgical; cognitive; and
other (which included physiotherapy studies and smoking
cessation trials). A final sample of 26 was purposively
selected for: initial evaluation tool feasibility assessment
(n = 1); pilot (n = 5); and full analysis (n = 20).
Evaluation tool
Development of the evaluation tool has been described
elsewhere [34]. In brief, the tool is divided into two sec-
tions: items derived from the IPDAS (Section A, 32 items)
and additional items derived from published guidelines for
informed consent (Section B, 27 items) [34]. The two sec-
tions are made up of a total of 59 items.
Data collection
For the purposes of this study, the study team (KG, WH,
ZS and SC) carried out an initial evaluation of one PIL
to assess whether it was feasible to use the tool to assess
PILs from UK RCTs. This was necessary as the tool was
developed based on the informational requirements for
US and Canadian PILs [34], which differ from UK
guidelines with regard to whether specific information
is presented in the information sheet or consent form.
The team then discussed items for meaning and clarifi-
cation and developed a coding ‘manual’, which con-
tained detailed description of rules for coding, to assist
in the analysis (for example, see Additional file 1). In
developing the coding manual we opted to rate items
using a two-point scale, rather than the four-point
scale originally reported. This approach was taken as it
is difficult to make a clear distinction between both
strongly agree and agree, and strongly disagree and
disagree. The two-point scale was defined as follows:
‘agree’ (that is, information was present) or ‘disagree’
(information was absent), with some items (n = 5) including
a ‘not applicable’ option. Two researchers (KG and WH)
carried out further pilot assessment using the amended
scale. They independently rated five PILs using the tool and
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which were then discussed by the study team and used to
further refine the coding manual. Changes to the coding
manual following this pilot stage included clarifying the
focus for each question, for example question 1: ‘On the
first page of the PIL there is a description that potential
participants need to make a decision about whether or
not to participate in the trial’. The focus for this question
was determined as ‘potential participants need to make
a decision’ and the PIL was required to state this expli-
citly (for example you need to make a decision about
whether or not to participate) rather than implicitly,
through wording such as ‘you are being invited to par-
ticipate in a trial’. Further details on items included in
the tool and the coding rules associated with them can
be seen in Additional file 1. The evaluation scores gen-
erated from the five PILs included in the pilot stage are
not reported.
The 20 PILs sampled for full analysis were rated inde-
pendently using the tool by two members of the research
team (KG and WH). Evaluation scores for each PIL were
recorded and discrepancies were resolved using a third
researcher (SC) and the majority decision recorded.
Readability scores were calculated using an online Flesch-
Kincaid readability calculator [37]. The Flesch-Kincaid
algorithm is based on word length and sentence length,
where higher scores indicate material that is easier to
read and lower scores indicate material that is harder
to read, with scores being presented out of 100 [37]. Word
count was measured using the appropriate function in
Microsoft Word. Correlation coefficients were used to test
the relationship between readability and tool score, and
word count and tool score.
Analysis
Items on the tool were scored as follows: agree = 1 and
disagree = 0. Therefore, the maximum evaluation score
for a PIL was 59. Where the ‘not applicable’ option was
selected, the item was not scored and, for the calculation
of percentage score, the denominator was reduced by
1. Data from the evaluation tool scores were presented
as raw data and as percentages. Higher scores indicate
PILs which performed better when applying the evalu-
ation tool.
Inter-rater reliability between the two independent
researchers was assessed for the final sample of 20 PILs
using unweighted Cohen’s kappa. Pearson correlation
coefficients were calculated using IBM SPSS Statistics
(IBM Corporation, Armonk, NY, USA), and used to
test the relationship between readability and tool score,
and word count and tool score. A one-way ANOVA,
calculated using IBM SPSS Statistics, was used to test
differences in mean group scores between the inter-
vention groups.Results
Patient information leaflets
The 20 PILs included in the final analysis contained five
PILs from each of the intervention groups; drug; surgical;
cognitive; and other. PILs from all 19 CTUs were included
in the final sample and the majority of PILs (16/20) were
produced on, or after, 2006 (Additional file 2).
Evaluation scores
Inter-rater reliability was confirmed with an overall
mean kappa score of 0.846. There was variability in total
evaluation scores across the sample (Table 1). The high-
est evaluation score recorded was 38 (64%), while the
lowest was 19 (33%). Thirteen (65%) PILs scored a total
of 50% or less.
The evaluation scores for Section A ranged from 16%
to 41%. Evaluation scores for Section B were higher,
ranging from 46% to 91%. There were sub-sections
within Section A that scored consistently poorly. These
were: presenting probabilities; clarifying and expressing
values; structured guidance in deliberation and communi-
cation; and using evidence. The ‘presenting probabilities’
sub-section, which contains eight items, was scored as
‘0’ across all PILs and as such was the worst performing
sub-section.
There was no statistically significant difference (P = 0.119)
in mean evaluation scores between intervention groups
(Table 2). Similarly, there was no statistically significant
difference in mean evaluation scores between intervention
groups for Section A (P = 0.097) or Section B (P = 0.209)
(Table 2).
Evaluation score and readability
Readability scores ranged from 49 to 75 with a mean score
of 60.8 (SD = 6.4) (scores of 60 to 70 suggest understanding
by 13- to 15-year-olds). There were no statistically sig-
nificant differences in mean readability scores between
the intervention groups (P = 0.449; Table 2). Readabil-
ity did not correlate with evaluation score (r = −0.372,
P = 0.106; Figure 1).
Evaluation score and word count
Word count ranged from 698 to 4,138 words, with a
mean word count of 1,853 (SD = 960). There were no
statistically significant differences in word count between
intervention groups (P = 0.224; Table 2). However, un-
like readability, word count had a positive correlation
with evaluation score and was statistically significant
(r = 0.802, P <0.01; Figure 2).
Discussion
This study evaluated PILs from UK RCTs using an
evaluation tool based on the IPDAS [33] and informed
consent guidelines.
Table 1 Scores for patient information leaflets
Number Overall
score
(n/59)
Score for
section
A (n/32)
Score for
section
B (n/27)
Scores of sub-sections
Score for sub-sections in section A Score for sub-sections in section B
Providing
information about
options in sufficient
detail to make a
decision (n/12)
Presenting
probabilities
(n/8)
Clarifying and
expressing
values (n/2)
Structured
guidance in
deliberation and
communication
(n/2)
Using
evidence
(n/4)
Disclosure and
transparency
(n/4)
Key
elements
(n/10)
Ethical
issues
(n/5)
Study
design
(n/5)
Formatting
(n/6)
Style
(n/1)
Drug interventions
01 31 (53%)* 10 (31%) 21 (81%)* 5 0 0 0 1 4 7 4 4 5* 1
02 26 (45%)* 9 (28%) 17 (65%)* 5 0 0 0 1 3 6 3 3 4* 1
03 38 (64%) 13 (41%) 25 (93%) 6 0 1 1 2 3 9 4 5 6 1
04 29 (50%)* 9 (28%) 20 (77%)* 4 0 0 0 1 4 8 3* 3 5 1
05 33 (57%)* 11 (34%) 22 (85%)* 6 0 0 1 1 3 10 3 3 5* 1
Surgical interventions
06 33 (56%) 12 (38%) 21 (78%) 6 0 1 0 1 4 8 4 3 5 1
07 19 (33%)* 7 (22%) 12 (46%)* 2 0 0 1 1 3 3 2 1 5* 1
08 26 (44%) 8 (25%) 18 (67%) 2 0 0 1 1 4 7 3 4 4 0
09 33 (56%) 10 (31%) 23 (85%) 4 0 0 1 1 4 9 3 4 6 1
10 24 (41%)* 6 (19%) 18 (69%)* 3 0 0 0 1 2 5 3 4 5* 1
Cognitive interventions
11 23 (40%)* 6 (19%) 17 (65%)* 2 0 0 0 1 3 8 1 3 4* 1
12 26 (46%)** 7 (22%) 19 (76%)** 1 0 0 1 1 4 8 1* 4 5* 1
13 21 (37%)** 5 (16%) 16 (64%)** 3 0 0 0 0 2 7 0* 3 5* 1
14 23 (40%)* 7 (22%) 16 (62%)* 3 0 0 0 1 3 7 1 3 4* 1
15 28 (48%)* 11 (34%) 17 (65%)* 7 0 0 0 1 3 8 0 3 5* 1
Other interventions
16 24 (42%)** 6 (19%) 18 (72%)** 2 0 0 0 1 3 7 2* 3 5* 1
17 31 (54%)** 10 (31%) 21 (84%)** 5 0 0 0 1 4 9 2* 4 5* 1
18 22 (39%)** 6 (19%) 16 (64%)** 2 0 0 0 1 3 6 2* 2 5* 1
19 30 (53%)** 9 (28%) 21 (84%)** 4 0 0 1 2 2 9 2* 4 5* 1
20 22 (39%)** 5 (16%) 17 (68%)** 2 0 0 0 0 3 7 2* 2 5* 1
*Denominator for overall score, and Section B, reduced by 1 (n = 58 and n = 26, respectively) due to scoring one item as not applicable; **denominator for overall score, and Section B, reduced by 2 (n = 57 and n = 25,
respectively) due to scoring two items as not applicable.
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Table 2 Comparison of intervention group mean scores
Mean Intervention group P value
Drug Surgical Cognitive Other
Overall score (SD) 31 (5) 27 (6) 24 (3) 26 (4) 0.119*
Section A score (SD) 10 (2) 9 (2) 7 (2) 7 (2) 0.097*
Section B score (SD) 21 (4) 18 (3) 17 (1) 19 (2) 0.209*
Readability (SD) 57.8 (5.6) 59.9 (4.0) 60.8 (8.0) 64.5 (7.4) 0.449*
Word count (SD) 2,572 (1,197) 1,896 (979) 1,523 (623) 1,422 (754) 0.224*
P, statistical significance of ANOVA test of scores across intervention groups; SD, standard deviation. *Not statistically significant.
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by an ethics committee and had been given a favourable
opinion. Despite this, we found that the majority of PILs
did not perform well using the tool (based on a score of less
than 50%). All the PILs scored more poorly on Section A as
compared to Section B. Our results provide an indication
that information shown to support high quality decision
making in other contexts is lacking in PILs for UK RCTs.
There were four sub-sections in Section A that scored
consistently poorly across all leaflets. These sub-sections
were: presenting probabilities; clarifying and expressing
values; structured guidance in deliberation and commu-
nication; and using evidence. This was not surprising
given these concepts are not currently included in the
informed consent guidance [1,4]. However, the items
reflect standards that have been shown to be important to
promote high quality decisions for treatment and screening
[25] and identify items that have also been shown to be im-
portant to trial participants during their trial participation
experience [27]. Moreover, our findings are mirrored in aFigure 1 Correlation of readability and overall score.similar study by Brehaut and colleagues, who also demon-
strate an absence or lack of detail related to these items in
PILs developed for trials in other contexts [34]. Perhaps
also unsurprisingly, in our study, scores for Section B were
better than scores for Section A. This is perhaps because
many of the items included in Section B are present within
the current guidelines for informed consent documents
[1,3]. Our findings suggest that the information presented
in PILs to date has tended to focus on key elements of
the RCT rather than supporting the process for decision
making. As highlighted earlier, arguably this relates to
conceptualisations of trial participation as being merely an
act or a process of informed consent. As such, we propose
reconsideration of the purpose of PILs and their role in the
informed consent process. We would support a move to a
more informed decision making process which encourages
potential participants to assess what matters to them and
how trial participation relates to them personally as individ-
uals. This study provides further evidence that PILs do
not include information that has been shown to improve
Figure 2 Correlation of word count and overall score.
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suggest that poor quality decisions are being made about
trial participation and indicates room for improvement.
There is evidence that some of the items identified as
lacking from PILs, which were measured in Section A,
may have an important role to play in decision making
for participation in RCTs. For example, the section on
‘presenting probabilities’ was lacking in most PILs, but
aspects of this concept have been shown to be important
for decisions about trial participation. In a recent study,
parents were faced with a hypothetical decision about
inclusion of their child in a RCT of paediatric postop-
erative pain control. Parents who received probabilistic
risk information in pictograph form (a diagram that
conveys meaning through pictorial resemblance) under-
stood the information better than those who received
information as words or tables [35]. Also, exercises to
help patients clarify and express their values, that is, to
determine what matters most to them, have been shown
to play a potentially important role in decision making for
potential RCT participants [30]. A recent study provided
potential participants with values clarification exercises
when considering participation in a hypothetical trial for
breast cancer treatment [30]. These exercises were found
to be beneficial in this context as they enabled effective
deliberation about the decision by lowering ambivalence
and decisional uncertainty and improving the clarity of
personal values [30]. Such exercises were also identified
as lacking in the PILs in this study. Lastly, another of the
areas which scored consistently poorly across the PILs
was structured guidance in deliberation and communi-
cation. This type of information could be incorporatedby including text such as ‘take time to think about how
you would feel if you received treatment A rather than
treatment B, and how the possible side effects of each
would affect you personally’ and ‘think carefully about
your decision to participate and how it might impact on
your life, take time to discuss with family and friends’, and
so on. However, the impact and usefulness of such infor-
mation requires investigation. To our knowledge there is
no published research into using structured guidance in
deliberation and communication within RCT PILs.
There was no correlation identified between readability
and tool score. Interestingly, the average readability level
of the PILs in this study (13 to 15 years) is well above the
estimated reading age of the UK population in general
(9 years) [38]. It is worth noting that readability formulae
(such as Flesch-Kincaid) have limitations in that they
test ‘structure and composition’ rather than meaning
or context. In addition they do not take into account
additional influences on ‘readability’ such as layout, ap-
pearance, print size, and use of diagrams [38]. However,
there was a significant correlation between word count
and tool score. This may be expected as longer PILs can
incorporate more information and thus potentially score
higher on the evaluation tool. We are not, however, pro-
moting the lengthening of existing PILs, which have
previously been noted as getting longer whilst not ne-
cessarily improving understanding [39]. It is possible to
write shorter PILs whilst improving the overall evalu-
ation score and being in accord with current guidance
from ethics committees, as evident from some of the
PILs included in this study. For example, PIL01 and
PIL17 (word count 1,500 to 2,000) scored higher than
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PIL15 (word count 2,500 to 3,000)). It may be that the
tool should include consideration of word count to ac-
commodate any effect of the number of words in the
PIL. Therefore, it may be helpful to develop a frame-
work from the evaluation tool for those writing PILs for
RCTs to encourage them to include text that might fa-
cilitate better quality decisions which are more aligned
with promoting ‘informed’ consent.
Strengths and limitations
The primary strength of this study is that it investigated
the content of a sample of UK PILs, considering the ex-
tent to which they contained key information which is
known to support decision making in other contexts. A
further strength of the study is that each PIL was scored
by two researchers independently, so as not to introduce
rater bias. This study is the first to report the use of
Section B of the tool which was developed with the
specific aim of assessing consent forms in a US and
Canadian context. As discussed earlier, consent forms
for US trials are often considerably longer than those
in the UK (where they are generally a single page) and
much of the information contained within US consent
forms would be found in a PIL in the UK. Therefore,
we felt it was appropriate to use both sections of the
tool to assess UK PILs.
We undertook this study as a feasibility study to assess
whether the tool could be used to evaluate PILs from
UK-based RCTs, and as such, our sample was small.
Although taken from a convenience sample, PILs were
sampled purposively to ensure that there was represen-
tativeness of CTUs (so as not to introduce any bias
from developers) and intervention type across the sam-
ple. As we sourced only publicly available PILs from
CTU websites, the number of PILs identified is likely
to be much smaller than the number of RCTs on-going
or recently completed in the UK. Moreover, CTUs may
be selective with regard to which PILs they make publicly
available on their websites. Despite these potential limita-
tions, we found both variability in scores between PILs and
consistency in terms of which sub-sections the PILs scored
poorly on. This suggests that our findings may be generalis-
able, and have relevance to a wider range of PILs for UK
RCTs. We restricted our sample to PILs dated from 2001
onwards (to align with the introduction of the European
Clinical Trials Directive [36]). Although it is possible that
PILs written more recently may score better on the tool,
partly because of updates to UK guidance [4], we did not
find evidence of an association between year of publication
and tool score (r = −0.136, P = 0.566). In addition, the
majority of the PILs included in our study (16/20) were
produced after 2006, and so are likely to conform to the
most recent UK guidance documents [4].Key recommendations
As is evident from existing studies, changing the struc-
ture of information contained within PILs often has little
or no effect on knowledge or understanding. However,
the findings from this study support new ways of thinking
about the information to include in a PIL, which may be
more encompassing for supporting high quality decision
making, and as such, more aligned with the process of
‘informed’ decision making relating to consent. There-
fore to improve decision quality with regard to making
decisions about trial participation, it may be important
to incorporate, or at least consider inclusion of, these
items into PILs. The preliminary findings from other
studies do offer promise for the use of decision aids,
and associated aspects, within the context of informed
consent for clinical trials [28-30,35]. We believe there
may be potential benefit from the use of decision aids
in this context. However, there is currently insufficient
evidence to propose a definitive model to improve the
existing process such that it aligns more with ‘informed
decisions’ for trial participation or to recommend writing
PILs to IPDAS standards. At present, suggestions for
researchers could be to evaluate their own PILs using
the tool, equivalent frameworks developed from the
IPDAS or explore those items identified in this study
as lacking from existing PILs. Any areas which score
poorly could be supplemented before the PILs are used in
the informed consent process and piloted with potential
participants to discuss support for decision making. How-
ever, before this could be implemented, empirical studies
assessing whether any of these items are associated with
an improvement in decision making are required.
It should be recognised that PILs form only one piece
of the jigsaw for supporting decisions about trial partici-
pation and that decision making in this context is often
influenced by much more than just the provided informa-
tion [27]. We propose that existing PILs need to be re-
placed, or supplemented, with interventions that are more
suited to supporting informed decision making. This may
be a decision aid but may also be a strategy for improved
communication. It is worth noting that more informed
decisions about participation in RCTs may impact either
negatively or positively on both recruitment and retention
within a study. We postulate that participants who are
more fully informed at the outset and more aware of the
likely expectations on them throughout their participation
experience may be less likely to drop out, but this remains
to be determined empirically.
Engagement with key stakeholders such as ethics com-
mittees, policy makers, patients and trialists could help
to incorporate the findings from this research into the
development process for PILs, and pave the way for new
ways of thinking about supporting informed decisions in
the context of RCT participation.
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We have shown that the evaluation tool can be used to
assess whether or not PILs from UK RCTs include items
recommended for good quality decision making. Existing
PILs for participation in UK RCTs fulfil ethics committee
guidelines [1], yet we found that many were lacking in
items deemed to be important for promoting high quality
decisions. Future research could explore the potential
value of the type of information identified as lacking from
existing PILs and whether this would better support po-
tential participants to make high quality decisions about
participation in RCTs.
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Additional file 2: Description of trials included in patient
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